| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 75.65 | 6.3% |
| Total Income | 76.34 | 7.4% |
| Expenditure | 76.14 | 6.5% |
| PBT | 0.21 | 157.2% |
| Net Profit | -0.23 | 42.7% |
| OPM | 0.16% | 0.02pp |
| NPM | -0.30% | 0.26pp |
| EPS | 0.74 | 42.6% |
Samrat Pharmachem Ltd. Reports Q1 FY2025 Financial Results with 10.6% YoY Revenue Growth
13 Aug 2025 · 13 Aug 2025, 09:22 pm
Summary
Samrat Pharmachem Ltd. has reported its financial results for Q1 FY2025 with a 10.6% year-over-year revenue growth. The company's revenue from operations stands at INR 7,565.16 lakhs, with a profit before tax of INR 20.78 lakhs. The company is a single-segment business, manufacturing pharmaceutical chemicals.
Key Highlights
- 1
Q1 FY2025 revenue growth of 10.6% YoY
- 2
Revenue from operations: INR 7,565.16 lakhs
- 3
Profit before tax: INR 20.78 lakhs
- 4
Manufacturers & Exporters of Pharmaceutical Chemicals
- 5
Single business segment: pharmaceutical chemicals
Management Comments
LALIT DAMODAR MEHTA
The above results were reviewed by the Audit Committee of the Board of Directors. The above results have been taken on record by the Board of Directors at its Meeting held on Wednesday, August 13, 2025 at the Corporate Office of the Company.
Informational and educational content only. Not investment advice.